Basic HTML Version
© The Canadian Journal of Urology™; 18(Supplement 1); April 2011
13
11. Corcos J, Gajewski J, Heritz D et al. Canadian Urological
Association guidelines on urinary incontinence.
Can J Urol
2006;13(3):3127-3138.
12. Staskin DR. Overactive bladder in the elderly: a guide to
pharmacological management.
Drugs Aging
2005;22(12):1013-
1028.
13. Ouslander JG. Geriatric considerations in the diagnosis and
management of overactive bladder.
Urology
2002;60(Suppl
5A):50-55.
14. KayGG.Anticholinergic therapy for OAB: cognitive implications
for an at-risk geriatric population.
Clin Ger
2007;15(Suppl 2):10-
14.
15. Kay GG. Adverse cognitive effects of anticholinergic
therapy: treating OAB in geriatric patients.
OBG Management
2007;19(Suppl 3):11-14.
16. Kay G, Crook T, Rekeda L et al. Differential effects of the
antimuscarinic agents darifenacin and oxybutynin ER on
memory in older subjects.
Eur Urol
2006;50(2):317-326.
17. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot
study assessing the risk of cognitive impairment or sedation
in the elderly following single doses of solifenacin 10 mg.
Expert Opin Drug Saf
2009;8(6):15-26.
18. Anderson RU, MacDiarmid S, Kell S, Barada JH, Serels S,
Goldberg RP. Effectiveness and tolerability of extended-release
oxybutynin vs extended-release tolterodine in women with or
without prior anticholinergic treatment for overactive bladder.
Int Urogynecol J Pelvic Floor Dysfunct
2006;17(5):502-511.
19. Desmopressin 2008 advisory. Available at http://www.
hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2008/
desmopressin_hpc-cps-eng.php Accessed March 30, 2011.
20. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release
attenuates lower urinary tract symptoms in men with benign
prostatic hyperplasia.
J Urol
2005;174(6):2273-2276.
21. Abrams P, Kaplan S, De Koning Gans HJ, Millard R.
J Urol
2006;175(3 Pt 1):999-1004.
22. Andersson KE, de Groat WC, McVary KT et al. Tadalafil for the
treatment of lower urinary tract symptoms secondary to benign
prostatic hyperplasia: pathophysiology and mechanism(s) of
action.
Neurourol Urodyn
2011;30(3):292-301.
Overactive bladder